The multifactorial etiology of inhibitor development in hemophilia: Genetics and environment

Seminars in Thrombosis and Hemostasis

Volumn 35, Issue 8, 2009, Pages 723-734

  Gouw, Samantha C ^a   Van Den Berg, H Marke ^b,c  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c MEANDER MEDICAL CENTER   (Netherlands)

Author keywords

Factor VIII inhibitors; Factor VIII mutation; Genetic polymorphisms; Intensive treatment; Prophylaxis; Risk factors

Indexed keywords

BLOOD CLOTTING FACTOR 8; TRANSFORMING GROWTH FACTOR BETA;

BREAST FEEDING; CONTINUOUS INFUSION; DISEASE COURSE; ENVIRONMENTAL FACTOR; ETHNICITY; EXTRAVASATION; FAMILY HISTORY; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HEMOPHILIA A; HEMOPHILIA B; HEREDITY; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOMODULATION; OBSERVATIONAL STUDY; ONSET AGE; PRIORITY JOURNAL; REVIEW;

AGE FACTORS; ANIMALS; BLOOD COAGULATION FACTOR INHIBITORS; ENVIRONMENT; FACTOR IX; FACTOR VIII; HEMOPHILIA A; HEMOPHILIA B; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; INFANT; POLYMORPHISM, GENETIC; RECOMBINANT PROTEINS; RISK FACTORS;

EID: 77449116760     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0029-1245105     Document Type: Review

References (102)

1. White G C. II, Rosendaal F, Aledort L M., Lusher J M., Rothschild C, Ingerslev J, Factor VIII and Factor IX Subcommittee. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 2001 85 (3) 560
2. Plug I, Peters M, Mauser-Bunschoten E P. et al. Social participation of patients with hemophilia in the Netherlands. Blood 2008 111 (4) 1811-1815
3. DiMichele D. Inhibitor development in haemophilia B: an orphan disease in need of attention. Br J Haematol 2007 138 (3) 305-315
4. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 2003 9 (4) 418-435
5. Kempton C L., Soucie J M., Abshire T C. Incidence of inhibitors in a cohort of 838 males with hemophilia A previously treated with factor VIII concentrates. J Thromb Haemost 2006 4 (12) 2576-2581
6. Darby S C., Keeling D M., Spooner R J. et al, UK Haemophilia Centre Doctors' Organisation. The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 197799. J Thromb Haemost 2004 2 (7) 1047-1054
7. Morfini M, Haya S, Tagariello G et al. European study on orthopaedic status of haemophilia patients with inhibitors. Haemophilia 2007 13 (5) 606-612
8. Gringeri A, Mantovani L G., Scalone L, Mannucci P M., COCIS Study Group. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood 2003 102 (7) 2358-2363
9. Wight J, Paisley S, Knight C. Immune tolerance induction in patients with haemophilia A with inhibitors: a systematic review. Haemophilia 2003 9 (4) 436-463 (Pubitemid 36874392)
10. Donfield S M., Lynn H S., Lail A E., Hoots W K., Berntorp E, Gomperts E D., for the Hemophilia Growth and Development Study Group. Delays in maturation among adolescents with hemophilia and a history of inhibitors. Blood 2007 110 (10) 3656-3661
11. Kershaw G, Jayakodi D, Dunkley S. Laboratory identification of factor inhibitors: the perspective of a large tertiary hemophilia centre. Semin Thromb Hemost 2009 35 (8) 760-768
12. Verbruggen B, Novakova I, Wessels H, Boezeman J, van den Berg M, Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost 1995 73 (2) 247-251
13. Peerschke E I., Castellone D D., Ledford-Kraemer M, Van Cott E M., Meijer P, NASCOLA Proficiency Testing Committee. Laboratory assessment of factor VIII inhibitor titer: the North American Specialized Coagulation Laboratory Association experience. Am J Clin Pathol 2009 131 (4) 552-558
14. Schwaab R, Brackmann H H., Meyer C et al. Haemophilia A: mutation type determines risk of inhibitor formation. Thromb Haemost 1995 74 (6) 1402-1406
15. Goodeve A C., Williams I, Bray G L., Peake I R., Recombinate PUP Study Group. Relationship between factor VIII mutation type and inhibitor development in a cohort of previously untreated patients treated with recombinant factor VIII (Recombinate). Thromb Haemost 2000 83 (6) 844-848
16. Astermark J, Oldenburg J, Escobar M, White G C. II, Berntorp E, Malm International Brother Study group. The Malm International Brother Study (MIBS). Genetic defects and inhibitor development in siblings with severe hemophilia A. Haematologica 2005 90 (7) 924-931
17. Vinciguerra C, Zawadzki C, Dargaud Y et al. Characterisation of 96 mutations in 128 unrelated severe haemophilia A patients from France. Description of 62 novel mutations. Thromb Haemost 2006 95 (4) 593-599
18. Tuddenham E G., McVey J H. The genetic basis of inhibitor development in haemophilia A. Haemophilia 1998 4 (4) 543-545
19. Oldenburg J, Brackmann H H., Schwaab R. Risk factors for inhibitor development in hemophilia A. Haematologica 2000 85 (Suppl 10) 7-13 discussion 13-14
20. Goodeve A C., Peake I R. The molecular basis of hemophilia A: genotype-phenotype relationships and inhibitor development. Semin Thromb Hemost 2003 29 (1) 23-30
21. Oldenburg J, Schrder J, Schmitt C, Brackmann H H., Schwaab R. Small deletion/insertion mutations within poly-A runs of the factor VIII gene mitigate the severe haemophilia A phenotype. Thromb Haemost 1998 79 (2) 452-453
22. Frommel D, Allain J P. Genetic predisposition to develop factor VIII antibody in classic hemophilia. Clin Immunol Immunopathol 1977 8 (1) 34-38
23. Shapiro S S. Genetic predisposition to inhibitor formation. Prog Clin Biol Res 1984 150 45-55
24. Astermark J, Berntorp E, White G C., Kroner B L., MIBS Study Group. The Malm International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients. Haemophilia 2001 7 (3) 267-272
25. Aledort L M., Dimichele D M. Inhibitors occur more frequently in African-American and Latino haemophiliacs. Haemophilia 1998 4 (1) 68
26. Scharrer I, Bray G L., Neutzling O. Incidence of inhibitors in haemophilia A patientsa review of recent studies of recombinant and plasma-derived factor VIII concentrates. Haemophilia 1999 5 (3) 145-154
27. Viel K R., Ameri A, Abshire T C. et al. Inhibitors of factor VIII in black patients with hemophilia. N Engl J Med 2009 360 (16) 1618-1627
28. Hay C R., Ollier W, Pepper L et al, UKHCDO Inhibitor Working Party. HLA class II profile: a weak determinant of factor VIII inhibitor development in severe haemophilia A. Thromb Haemost 1997 77 (2) 234-237
29. Oldenburg J, Picard J K., Schwaab R, Brackmann H H., Tuddenham E G., Simpson E. HLA genotype of patients with severe haemophilia A due to intron 22 inversion with and without inhibitors of factor VIII. Thromb Haemost 1997 77 (2) 238-242
30. Frommel D, Allain J P., Saint-Paul E et al. HLA antigens and factor VIII antibody in classic hemophilia. European study group of factor VIII antibody. Thromb Haemost 1981 46 (4) 687-689
31. Mayr W R., Lechner K, Niessner H, Pabinger-Fasching I. HLA-DR and factor VIII antibodies in hemophilia A. Thromb Haemost 1984 51 (2) 293
32. Lippert L E., Fisher L M., Schook L B. Relationship of major histocompatibility complex class II genes to inhibitor antibody formation in hemophilia A. Thromb Haemost 1990 64 (4) 564-568
33. Astermark J, Oldenburg J, Carlson J et al. Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A. Blood 2006 108 (12) 3739-3745
34. Shapiro S S. Markers for the factor VIII antibody response in hemophilia A. Scand J Haematol Suppl 1984 40 181-185
35. Alper C A., Raum D D., Awdeh Z L., Shapiro S S., Yunis E J. Major histocompatibility complex (MHC)-linked complement alleles as markers for the development of anti-factor VIII in hemophiliacs. Prog Clin Biol Res 1984 150 141-142
36. Simonney N, De Bosch N, Argueyo A, Garcia E, Layrisse Z. HLA antigens in hemophiliacs A with or without factor VIII antibodies in a Venezuelan mestizo population. Tissue Antigens 1985 25 (4) 216-219
37. Papasteriades C, Varla M, Economidou J et al. High frequency of HLA-DR5 in Greek patients with haemophilia A and haemophilia B. Tissue Antigens 1986 28 (2) 84-87
38. Aly A M., Aledort L M., Lee T D., Hoyer L W. Histocompatibility antigen patterns in haemophilic patients with factor VIII antibodies. Br J Haematol 1990 76 (2) 238-241
39. Ohta H, Takahashi I, Kojima T et al. Histocompatibility antigens and alleles in Japanese haemophilia A patients with or without factor VIII antibodies. Tissue Antigens 1999 54 (1) 91-97
40. Wieland I, Wermes C, Eifrig B et al. Inhibitor-Immunology-Study. Different HLA-types seem to be involved in the inhibitor development in haemophilia A. Hamostaseologie 2008 28 (suppl 1) S26-S28
41. Ragni M V., Ojeifo O, Feng J et al. Risk factors for inhibitor formation in haemophilia: a prevalent case-control study. Haemophilia 2009 15 (5) 1074-1082
42. Astermark J, Oldenburg J, Pavlova A, Berntorp E, Lefvert A K., MIBS Study Group. Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A. Blood 2006 107 (8) 3167-3172
43. Astermark J, Wang X, Oldenburg J, Berntorp E, Lefvert A K., MIBS Study Group. Polymorphisms in the CTLA-4 gene and inhibitor development in patients with severe hemophilia A. J Thromb Haemost 2007 5 (2) 263-265
44. Berntorp E, Astermark J, Donfield S M. et al, Hemophilia Inhibitor Genetics Study. Haemophilia Inhibitor Genetics Studyevaluation of a model for studies of complex diseases using linkage and association methods. Haemophilia 2005 11 (4) 427-429
45. Lorenzo J I., Lpez A, Altisent C, Aznar J A. Incidence of factor VIII inhibitors in severe haemophilia: the importance of patient age. Br J Haematol 2001 113 (3) 600-603
46. van der Bom J G., Mauser-Bunschoten E P., Fischer K, van den Berg H M. Age at first treatment and immune tolerance to factor VIII in severe hemophilia. Thromb Haemost 2003 89 (3) 475-479
47. Chalmers E A., Brown S A., Keeling D et al, Paediatric Working Party of UKHCDO. Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A. Haemophilia 2007 13 (2) 149-155
48. Santagostino E, Mancuso M E., Rocino A et al. Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study. Br J Haematol 2005 130 (3) 422-427
49. Gouw S C., van den Berg H M., le Cessie S, van der Bom J G. Treatment characteristics and the risk of inhibitor development: a multicenter cohort study among previously untreated patients with severe hemophilia A. J Thromb Haemost 2007 5 (7) 1383-1390
50. Gouw S C., van der Bom J G., Marijke van den Berg H. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 2007 109 (11) 4648-4654
51. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994 12 991-1045
52. Morado M, Villar A, Jimnez Yuste V, Quintana M, Hernandez Navarro F. Prophylactic treatment effects on inhibitor risk: experience in one centre. Haemophilia 2005 11 (2) 79-83
53. Hawiger D, Inaba K, Dorsett Y et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med 2001 194 (6) 769-779
54. Rosendaal F R., Nieuwenhuis H K., van den Berg H M. et al, Dutch Hemophilia Study Group. A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in The Netherlands. Blood 1993 81 (8) 2180-2186
55. Peerlinck K, Arnout J, Gilles J G., Saint-Remy J M., Vermylen J. A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate. Thromb Haemost 1993 69 (2) 115-118
56. Mauser-Bunschoten E P., Rosendaal F R., Nieuwenhuis H K., Roosendaal G, Brit E, van den Berg H M. Clinical course of factor VIII inhibitors developed after exposure to a pasteurised Dutch concentrate compared to classic inhibitors in hemophilia A. Thromb Haemost 1994 71 (6) 703-706
57. Brit E, Rosendaal F R. Inhibitors in hemophilia A: are some products safer? Semin Hematol 1994 31 (2, suppl 4) 11-15
58. Scharrer I, Ehrlich H J. Reported inhibitor incidence in FVIII PUP studies: comparing apples with oranges? Haemophilia 2004 10 (2) 197-198
59. Ettingshausen C E., Kreuz W. Recombinant vs. plasma-derived products, especially those with intact VWF, regarding inhibitor development. Haemophilia 2006 12 (suppl 6) 102-106
60. Kreuz W, Ettingshausen C E., Auerswald G, et al. Epidemiology of inhibitors and current treatment strategies. Haematologica 2003 88 (6) EREP04
61. Goudemand J, Rothschild C, Demiguel V et al, FVIII-LFB and Recombinant FVIII study groups. Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood 2006 107 (1) 46-51
62. Gouw S C., van der Bom J G., Auerswald G, Ettinghausen C E., Tedgrd U, van den Berg H M. Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study. Blood 2007 109 (11) 4693-4697
63. Suzuki T, Arai M, Amano K, Kagawa K, Fukutake K. Factor VIII inhibitor antibodies with C2 domain specificity are less inhibitory to factor VIII complexed with von Willebrand factor. Thromb Haemost 1996 76 (5) 749-754
64. Jacquemin M G., Saint-Remy J M. Factor VIII immunogenicity. Haemophilia 1998 4 (4) 552-557
65. Dasgupta S, Repess Y, Bayry J et al. VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors. Blood 2007 109 (2) 610-612
66. Wadhwa M, Dilger P, Tubbs J, Mire-Sluis A, Barrowcliffe T, Thorpe R. Identification of transforming growth factor-beta as a contaminant in factor VIII concentrates: a possible link with immunosuppressive effects in hemophiliacs. Blood 1994 84 (6) 2021-2030
67. Hodge G, Han P. Effect of factor VIII concentrate on antigen-presenting cell (APC)/T-cell interactions in vitro: relevance to inhibitor formation and tolerance induction. Br J Haematol 2000 109 (1) 195-200
68. Hodge G, Flower R, Han P. Effect of factor VIII concentrate on leucocyte cytokine production: characterization of TGF-beta as an immunomodulatory component in plasma-derived factor VIII concentrate. Br J Haematol 1999 106 (3) 784-791
69. Peerlinck K, Arnout J, Di Giambattista M et al. Factor VIII inhibitors in previously treated haemophilia A patients with a double virus-inactivated plasma derived factor VIII concentrate. Thromb Haemost 1997 77 (1) 80-86
70. Raut S, Weller L, Barrowcliffe T W. Phospholipid binding of factor VIII in different therapeutic concentrates. Br J Haematol 1999 107 (2) 323-329
71. Rosendaal F R. Factor VIII inhibitors on a DS-treated and pasteurized concentrate associated with specific batches and batch characteristics. Thromb Haemost 1997 77 590 Abstract OC-2407
72. Mannucci P M., Gringeri A, Peyvandi F, Santagostino E. Factor VIII products and inhibitor development: the SIPPET study (survey of inhibitors in plasma-product exposed toddlers). Haemophilia 2007 13 (suppl 5) 65-68
73. Baglin T, Beacham E. Is a change of factor VIII product a risk factor for the development of a factor VIII inhibitor? Thromb Haemost 1998 80 (6) 1036-1037
74. von Auer C, Oldenburg J, von Depka M et al. Inhibitor development in patients with hemophilia A after continuous infusion of FVIII concentrates. Ann N Y Acad Sci 2005 1051 498-505
75. Yee T T., Lee C A. Oral immune tolerance induction to factor VIII via breast milk, a possibility? Haemophilia 2000 6 (5) 591
76. Jansen I M., Fischer K, Van Der Bom J G., Van Den Berg H M. No protective effect of breastfeeding on inhibitor formation in severe hemophilia. Pediatr Hematol Oncol 2005 22 (7) 575-580
77. Knobe K E., Tengborn L I., Petrini P, Ljung R C. Breastfeeding does not influence the development of inhibitors in haemophilia. Haemophilia 2002 8 (5) 657-659
78. McMillan C W., Shapiro S S., Whitehurst D, Hoyer L W., Rao A V., Lazerson J. The natural history of factor VIII:C inhibitors in patients with hemophilia A: a national cooperative study. II. Observations on the initial development of factor VIII:C inhibitors. Blood 1988 71 (2) 344-348
79. Maclean P, Young D, Chalmers E. A case control study to examine treatment related factors in the development of inhibitors in haemophilia A. Haemophilia 2008 14 (Suppl 2) 44
80. Oldenburg J, Schwaab R, Brackmann H H. Induction of immune tolerance in haemophilia A inhibitor patients by the Bonn Protocol: predictive parameter for therapy duration and outcome. Vox Sang 1999 77 (Suppl 1) 49-54
81. Dimichele D M., Hay C R. The international immune tolerance study: a multicenter prospective randomized trial in progress. J Thromb Haemost 2006 4 (10) 2271-2273
82. Peng A, Gaitonde P, Kosloski M P. et al. Effect of route of administration of human recombinant factor VIII on its immunogenicity in hemophilia A mice. J Pharm Sci 2009 98 (12) 4480-4484
83. Ter Avest P C., Fischer K, Mancuso M E. et al. Risk stratification for inhibitor development at first treatment for severe hemophilia A: a tool for clinical practice. J Thromb Haemost 2008 6 (12) 2048-2054
84. Kurnik K, Thomas A E., European Paediatric Network for Haemophilia Management (PedNet). Meeting report: ninth and tenth workshops of the European Paediatric Network for Haemophilia Management (PedNet). Haemophilia 2007 13 (5) 658-662
85. Reipert B M., Sasgary M, Ahmad R U., Auer W, Turecek P L., Schwarz H P. Blockade of CD40/CD40 ligand interactions prevents induction of factor VIII inhibitors in hemophilic mice but does not induce lasting immune tolerance. Thromb Haemost 2001 86 (6) 1345-1352
86. Qian J, Collins M, Sharpe A H., Hoyer L W. Prevention and treatment of factor VIII inhibitors in murine hemophilia A. Blood 2000 95 (4) 1324-1329
87. Peng B, Ye P, Blazar B R. et al. Transient blockade of the inducible costimulator pathway generates long-term tolerance to factor VIII after nonviral gene transfer into hemophilia A mice. Blood 2008 112 (5) 1662-1672
88. Qadura M, Othman M, Waters B et al. Reduction of the immune response to factor VIII mediated through tolerogenic factor VIII presentation by immature dendritic cells. J Thromb Haemost 2008 6 (12) 2095-2104
89. Waters B, Qadura M, Burnett E et al. Anti-CD3 prevents factor VIII inhibitor development in hemophilia A mice by a regulatory CD4+CD25+-dependent mechanism and by shifting cytokine production to favor a Th1 response. Blood 2009 113 (1) 193-203
90. Lei T C., Scott D W. Induction of tolerance to factor VIII inhibitors by gene therapy with immunodominant A2 and C2 domains presented by B cells as Ig fusion proteins. Blood 2005 105 (12) 4865-4870
91. Schellekens H. Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin Ther 2002 24 (11) 1720-1740, discussion 1719
92. Dasgupta S, Navarrete A M., Bayry J et al. A role for exposed mannosylations in presentation of human therapeutic self-proteins to CD4+T lymphocytes. Proc Natl Acad Sci U S A 2007 104 (21) 8965-8970
93. van den Berg H M., Chalmers E A. Clinical prediction models for inhibitor development in severe hemophilia A. J Thromb Haemost 2009 7 (Suppl 1) 98-102
94. Hay C R., Ludlam C A., Colvin B T. et al. Factor VIII inhibitors in mild and moderate-severity haemophilia A. UK Haemophilia Centre Directors Organisation. Thromb Haemost 1998 79 (4) 762-766
95. Kemball-Cook G, Tuddenham E G., Wacey A I. The factor VIII Structure and Mutation Resource Site: HAMSTeRS version 4. Nucleic Acids Res 1998 26 (1) 216-219
96. D'Oiron R, Pipe S W., Jacquemin M. Mild/moderate haemophilia A: new insights into molecular mechanisms and inhibitor development. Haemophilia 2008 14 (Suppl 3) 138-146
97. Sharathkumar A, Lillicrap D, Blanchette V S. et al. Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A. J Thromb Haemost 2003 1 (6) 1228-1236
98. Eckhardt C L., Menke L A., van Ommen C H. et al. Intensive peri-operative use of factor VIII and the Arg593>Cys mutation are risk factors for inhibitor development in mild/moderate hemophilia A. J Thromb Haemost 2009 7 (6) 930-937
99. Belvini D, Salviato R, Radossi P et al, AICE HB Study Group. Molecular genotyping of the Italian cohort of patients with hemophilia B. Haematologica 2005 90 (5) 635-642
100. Chitlur M, Warrier I, Rajpurkar M, Lusher J M. Inhibitors in factor IX deficiency a report of the ISTH-SSC international FIX inhibitor registry (19972006). Haemophilia 2009 15 (5) 1027-1031
101. Thorland E C., Drost J B., Lusher J M. et al. Anaphylactic response to factor IX replacement therapy in haemophilia B patients: complete gene deletions confer the highest risk. Haemophilia 1999 5 (2) 101-105
102. Warrier I, Ewenstein B M., Koerper M A. et al. Factor IX inhibitors and anaphylaxis in hemophilia B. J Pediatr Hematol Oncol 1997 19 (1) 23-27